BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18561506)

  • 21. Beyond unfractionated heparin and warfarin: current and future advances.
    Hirsh J; O'Donnell M; Eikelboom JW
    Circulation; 2007 Jul; 116(5):552-60. PubMed ID: 17664384
    [No Abstract]   [Full Text] [Related]  

  • 22. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
    Wong CK; White HD
    Am J Cardiovasc Drugs; 2007; 7(4):249-57. PubMed ID: 17696566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR
    Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Direct thrombin antagonists].
    Lankes W; Fleischer K; Gulba DC
    Herz; 2001 Apr; 26 Suppl 1():46-52. PubMed ID: 11349627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failed thrombolysis in myocardial infarction.
    Qasim A; Chauhan A; More RS
    Int J Cardiol; 2000 Aug; 75(1):5-14. PubMed ID: 11054500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
    Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA;
    JAMA; 2006 Apr; 295(13):1519-30. PubMed ID: 16537725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hirudin and Hirulog.
    White H
    Aust N Z J Med; 1993 Dec; 23(6):769-70. PubMed ID: 8141724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bivalirudin: a direct thrombin inhibitor.
    Gladwell TD
    Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
    Bassand JP
    Haemostasis; 2000; 30 Suppl 2():114-21; discussion 106-7. PubMed ID: 11251354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulants in children and adolescents.
    Young G
    Hematology Am Soc Hematol Educ Program; 2015; 2015():111-6. PubMed ID: 26637709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
    Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
    N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
    Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
    Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
    Dangas G; Mehran R; Guagliumi G; Caixeta A; Witzenbichler B; Aoki J; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Rabbani LE; Parise H; Stone GW;
    J Am Coll Cardiol; 2009 Oct; 54(15):1438-46. PubMed ID: 19796737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention.
    Steg PG; van 't Hof A; Clemmensen P; Lapostolle F; Dudek D; Hamon M; Cavallini C; Gordini G; Huber K; Coste P; Thicoipe M; Nibbe L; Steinmetz J; Ten Berg J; Eggink GJ; Zeymer U; Campo dell' Orto M; Kanic V; Deliargyris EN; Day J; Schuette D; Hamm CW; Goldstein P
    Am Heart J; 2013 Dec; 166(6):960-967.e6. PubMed ID: 24268209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic therapy in ST-segment elevation myocardial infarction.
    Wong CK; White HD
    Expert Opin Pharmacother; 2011 Feb; 12(2):213-23. PubMed ID: 21226633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
    Weitz JI; Bates SM
    Arch Intern Med; 2000 Mar; 160(6):749-58. PubMed ID: 10737274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.